Does ADO-TRASTUZUMAB EMTANSINE Cause Neoplasm progression? 149 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 149 reports of Neoplasm progression have been filed in association with ADO-TRASTUZUMAB EMTANSINE. This represents 1.7% of all adverse event reports for ADO-TRASTUZUMAB EMTANSINE.
149
Reports of Neoplasm progression with ADO-TRASTUZUMAB EMTANSINE
1.7%
of all ADO-TRASTUZUMAB EMTANSINE reports
34
Deaths
36
Hospitalizations
How Dangerous Is Neoplasm progression From ADO-TRASTUZUMAB EMTANSINE?
Of the 149 reports, 34 (22.8%) resulted in death, 36 (24.2%) required hospitalization, and 7 (4.7%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADO-TRASTUZUMAB EMTANSINE. However, 149 reports have been filed with the FAERS database.
What Other Side Effects Does ADO-TRASTUZUMAB EMTANSINE Cause?
Nausea (780)
Fatigue (774)
Disease progression (750)
Diarrhoea (654)
Off label use (630)
Thrombocytopenia (519)
Death (509)
Neuropathy peripheral (506)
Headache (465)
Platelet count decreased (453)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which ADO-TRASTUZUMAB EMTANSINE Alternatives Have Lower Neoplasm progression Risk?
ADO-TRASTUZUMAB EMTANSINE vs ADRIAMYCIN
ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB
ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB-AVWA
ADO-TRASTUZUMAB EMTANSINE vs ADVAIR
ADO-TRASTUZUMAB EMTANSINE vs ADVAIR HFA